1 Market Overview 1.1 Product Overview and Scope of Skin and Soft Tissue Infection Treatment 1.2 Classification of Skin and Soft Tissue Infection Treatment by Type 1.2.1 Overview: Global Skin and Soft Tissue Infection Treatment Market Size by Type: 2017 Versus 2021 Versus 2028 1.2.2 Global Skin and Soft Tissue Infection Treatment Revenue Market Share by Type in 2021 1.2.3 Antibiotics 1.2.4 Anti-Fungal Agents 1.2.5 Others 1.3 Global Skin and Soft Tissue Infection Treatment Market by Application 1.3.1 Overview: Global Skin and Soft Tissue Infection Treatment Market Size by Application: 2017 Versus 2021 Versus 2028 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Ambulatory Surgical Centers 1.3.5 Others 1.4 Global Skin and Soft Tissue Infection Treatment Market Size & Forecast 1.5 Global Skin and Soft Tissue Infection Treatment Market Size and Forecast by Region 1.5.1 Global Skin and Soft Tissue Infection Treatment Market Size by Region: 2017 VS 2021 VS 2028 1.5.2 Global Skin and Soft Tissue Infection Treatment Market Size by Region, (2017-2022) 1.5.3 North America Skin and Soft Tissue Infection Treatment Market Size and Prospect (2017-2028) 1.5.4 Europe Skin and Soft Tissue Infection Treatment Market Size and Prospect (2017-2028) 1.5.5 Asia-Pacific Skin and Soft Tissue Infection Treatment Market Size and Prospect (2017-2028) 1.5.6 South America Skin and Soft Tissue Infection Treatment Market Size and Prospect (2017-2028) 1.5.7 Middle East and Africa Skin and Soft Tissue Infection Treatment Market Size and Prospect (2017-2028) 1.6 Market Drivers, Restraints and Trends 1.6.1 Skin and Soft Tissue Infection Treatment Market Drivers 1.6.2 Skin and Soft Tissue Infection Treatment Market Restraints 1.6.3 Skin and Soft Tissue Infection Treatment Trends Analysis 2 Company Profiles 2.1 Merck 2.1.1 Merck Details 2.1.2 Merck Major Business 2.1.3 Merck Skin and Soft Tissue Infection Treatment Product and Solutions 2.1.4 Merck Skin and Soft Tissue Infection Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.1.5 Merck Recent Developments and Future Plans 2.2 Wockhardt Limited 2.2.1 Wockhardt Limited Details 2.2.2 Wockhardt Limited Major Business 2.2.3 Wockhardt Limited Skin and Soft Tissue Infection Treatment Product and Solutions 2.2.4 Wockhardt Limited Skin and Soft Tissue Infection Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.2.5 Wockhardt Limited Recent Developments and Future Plans 2.3 Atox Bio Inc. 2.3.1 Atox Bio Inc. Details 2.3.2 Atox Bio Inc. Major Business 2.3.3 Atox Bio Inc. Skin and Soft Tissue Infection Treatment Product and Solutions 2.3.4 Atox Bio Inc. Skin and Soft Tissue Infection Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.3.5 Atox Bio Inc. Recent Developments and Future Plans 2.4 Durata Therapeutics (Teva) 2.4.1 Durata Therapeutics (Teva) Details 2.4.2 Durata Therapeutics (Teva) Major Business 2.4.3 Durata Therapeutics (Teva) Skin and Soft Tissue Infection Treatment Product and Solutions 2.4.4 Durata Therapeutics (Teva) Skin and Soft Tissue Infection Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.4.5 Durata Therapeutics (Teva) Recent Developments and Future Plans 2.5 Basilea Pharmaceutica AG 2.5.1 Basilea Pharmaceutica AG Details 2.5.2 Basilea Pharmaceutica AG Major Business 2.5.3 Basilea Pharmaceutica AG Skin and Soft Tissue Infection Treatment Product and Solutions 2.5.4 Basilea Pharmaceutica AG Skin and Soft Tissue Infection Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.5.5 Basilea Pharmaceutica AG Recent Developments and Future Plans 2.6 Melinta Therapeutics 2.6.1 Melinta Therapeutics Details 2.6.2 Melinta Therapeutics Major Business 2.6.3 Melinta Therapeutics Skin and Soft Tissue Infection Treatment Product and Solutions 2.6.4 Melinta Therapeutics Skin and Soft Tissue Infection Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.6.5 Melinta Therapeutics Recent Developments and Future Plans 2.7 Takeda Pharmaceutical 2.7.1 Takeda Pharmaceutical Details 2.7.2 Takeda Pharmaceutical Major Business 2.7.3 Takeda Pharmaceutical Skin and Soft Tissue Infection Treatment Product and Solutions 2.7.4 Takeda Pharmaceutical Skin and Soft Tissue Infection Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022) 2.7.5 Takeda Pharmaceutical Recent Developments and Future Plans 3 Market Competition, by Players 3.1 Global Skin and Soft Tissue Infection Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022) 3.2 Market Concentration Rate 3.2.1 Top 3 Skin and Soft Tissue Infection Treatment Players Market Share in 2021 3.2.2 Top 10 Skin and Soft Tissue Infection Treatment Players Market Share in 2021 3.2.3 Market Competition Trend 3.3 Skin and Soft Tissue Infection Treatment Players Head Office, Products and Services Provided 3.4 Skin and Soft Tissue Infection Treatment Mergers & Acquisitions 3.5 Skin and Soft Tissue Infection Treatment New Entrants and Expansion Plans 4 Market Size Segment by Type 4.1 Global Skin and Soft Tissue Infection Treatment Revenue and Market Share by Type (2017-2022) 4.2 Global Skin and Soft Tissue Infection Treatment Market Forecast by Type (2023-2028) 5 Market Size Segment by Application 5.1 Global Skin and Soft Tissue Infection Treatment Revenue Market Share by Application (2017-2022) 5.2 Global Skin and Soft Tissue Infection Treatment Market Forecast by Application (2023-2028) 6 North America by Country, by Type, and by Application 6.1 North America Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2028) 6.2 North America Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2028) 6.3 North America Skin and Soft Tissue Infection Treatment Market Size by Country 6.3.1 North America Skin and Soft Tissue Infection Treatment Revenue by Country (2017-2028) 6.3.2 United States Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 6.3.3 Canada Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 6.3.4 Mexico Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 7 Europe by Country, by Type, and by Application 7.1 Europe Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2028) 7.2 Europe Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2028) 7.3 Europe Skin and Soft Tissue Infection Treatment Market Size by Country 7.3.1 Europe Skin and Soft Tissue Infection Treatment Revenue by Country (2017-2028) 7.3.2 Germany Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 7.3.3 France Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 7.3.4 United Kingdom Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 7.3.5 Russia Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 7.3.6 Italy Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 8 Asia-Pacific by Region, by Type, and by Application 8.1 Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2028) 8.2 Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2028) 8.3 Asia-Pacific Skin and Soft Tissue Infection Treatment Market Size by Region 8.3.1 Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Region (2017-2028) 8.3.2 China Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 8.3.3 Japan Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 8.3.4 South Korea Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 8.3.5 India Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 8.3.6 Southeast Asia Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 8.3.7 Australia Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 9 South America by Country, by Type, and by Application 9.1 South America Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2028) 9.2 South America Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2028) 9.3 South America Skin and Soft Tissue Infection Treatment Market Size by Country 9.3.1 South America Skin and Soft Tissue Infection Treatment Revenue by Country (2017-2028) 9.3.2 Brazil Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 9.3.3 Argentina Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 10 Middle East & Africa by Country, by Type, and by Application 10.1 Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2028) 10.2 Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2028) 10.3 Middle East & Africa Skin and Soft Tissue Infection Treatment Market Size by Country 10.3.1 Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Country (2017-2028) 10.3.2 Turkey Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 10.3.3 Saudi Arabia Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 10.3.4 UAE Skin and Soft Tissue Infection Treatment Market Size and Forecast (2017-2028) 11 Research Findings and Conclusion 12 Appendix 12.1 Methodology 12.2 Research Process and Data Source 12.3 Disclaimer

List of Tables Table 1. Global Skin and Soft Tissue Infection Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028 Table 2. Global Skin and Soft Tissue Infection Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028 Table 3. Global Market Skin and Soft Tissue Infection Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028) Table 4. Global Skin and Soft Tissue Infection Treatment Revenue (USD Million) by Region (2017-2022) Table 5. Global Skin and Soft Tissue Infection Treatment Revenue Market Share by Region (2023-2028) Table 6. Merck Corporate Information, Head Office, and Major Competitors Table 7. Merck Major Business Table 8. Merck Skin and Soft Tissue Infection Treatment Product and Solutions Table 9. Merck Skin and Soft Tissue Infection Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 10. Wockhardt Limited Corporate Information, Head Office, and Major Competitors Table 11. Wockhardt Limited Major Business Table 12. Wockhardt Limited Skin and Soft Tissue Infection Treatment Product and Solutions Table 13. Wockhardt Limited Skin and Soft Tissue Infection Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 14. Atox Bio Inc. Corporate Information, Head Office, and Major Competitors Table 15. Atox Bio Inc. Major Business Table 16. Atox Bio Inc. Skin and Soft Tissue Infection Treatment Product and Solutions Table 17. Atox Bio Inc. Skin and Soft Tissue Infection Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 18. Durata Therapeutics (Teva) Corporate Information, Head Office, and Major Competitors Table 19. Durata Therapeutics (Teva) Major Business Table 20. Durata Therapeutics (Teva) Skin and Soft Tissue Infection Treatment Product and Solutions Table 21. Durata Therapeutics (Teva) Skin and Soft Tissue Infection Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 22. Basilea Pharmaceutica AG Corporate Information, Head Office, and Major Competitors Table 23. Basilea Pharmaceutica AG Major Business Table 24. Basilea Pharmaceutica AG Skin and Soft Tissue Infection Treatment Product and Solutions Table 25. Basilea Pharmaceutica AG Skin and Soft Tissue Infection Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 26. Melinta Therapeutics Corporate Information, Head Office, and Major Competitors Table 27. Melinta Therapeutics Major Business Table 28. Melinta Therapeutics Skin and Soft Tissue Infection Treatment Product and Solutions Table 29. Melinta Therapeutics Skin and Soft Tissue Infection Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 30. Takeda Pharmaceutical Corporate Information, Head Office, and Major Competitors Table 31. Takeda Pharmaceutical Major Business Table 32. Takeda Pharmaceutical Skin and Soft Tissue Infection Treatment Product and Solutions Table 33. Takeda Pharmaceutical Skin and Soft Tissue Infection Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022) Table 34. Global Skin and Soft Tissue Infection Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022) Table 35. Global Skin and Soft Tissue Infection Treatment Revenue Share by Players (2019, 2020, 2021, and 2022) Table 36. Breakdown of Skin and Soft Tissue Infection Treatment by Company Type (Tier 1, Tier 2 and Tier 3) Table 37. Skin and Soft Tissue Infection Treatment Players Head Office, Products and Services Provided Table 38. Skin and Soft Tissue Infection Treatment Mergers & Acquisitions in the Past Five Years Table 39. Skin and Soft Tissue Infection Treatment New Entrants and Expansion Plans Table 40. Global Skin and Soft Tissue Infection Treatment Revenue (USD Million) by Type (2017-2022) Table 41. Global Skin and Soft Tissue Infection Treatment Revenue Share by Type (2017-2022) Table 42. Global Skin and Soft Tissue Infection Treatment Revenue Forecast by Type (2023-2028) Table 43. Global Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2022) Table 44. Global Skin and Soft Tissue Infection Treatment Revenue Forecast by Application (2023-2028) Table 45. North America Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2022) & (USD Million) Table 46. North America Skin and Soft Tissue Infection Treatment Revenue by Type (2023-2028) & (USD Million) Table 47. North America Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2022) & (USD Million) Table 48. North America Skin and Soft Tissue Infection Treatment Revenue by Application (2023-2028) & (USD Million) Table 49. North America Skin and Soft Tissue Infection Treatment Revenue by Country (2017-2022) & (USD Million) Table 50. North America Skin and Soft Tissue Infection Treatment Revenue by Country (2023-2028) & (USD Million) Table 51. Europe Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2022) & (USD Million) Table 52. Europe Skin and Soft Tissue Infection Treatment Revenue by Type (2023-2028) & (USD Million) Table 53. Europe Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2022) & (USD Million) Table 54. Europe Skin and Soft Tissue Infection Treatment Revenue by Application (2023-2028) & (USD Million) Table 55. Europe Skin and Soft Tissue Infection Treatment Revenue by Country (2017-2022) & (USD Million) Table 56. Europe Skin and Soft Tissue Infection Treatment Revenue by Country (2023-2028) & (USD Million) Table 57. Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2022) & (USD Million) Table 58. Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Type (2023-2028) & (USD Million) Table 59. Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2022) & (USD Million) Table 60. Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Application (2023-2028) & (USD Million) Table 61. Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Region (2017-2022) & (USD Million) Table 62. Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue by Region (2023-2028) & (USD Million) Table 63. South America Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2022) & (USD Million) Table 64. South America Skin and Soft Tissue Infection Treatment Revenue by Type (2023-2028) & (USD Million) Table 65. South America Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2022) & (USD Million) Table 66. South America Skin and Soft Tissue Infection Treatment Revenue by Application (2023-2028) & (USD Million) Table 67. South America Skin and Soft Tissue Infection Treatment Revenue by Country (2017-2022) & (USD Million) Table 68. South America Skin and Soft Tissue Infection Treatment Revenue by Country (2023-2028) & (USD Million) Table 69. Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Type (2017-2022) & (USD Million) Table 70. Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Type (2023-2028) & (USD Million) Table 71. Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Application (2017-2022) & (USD Million) Table 72. Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Application (2023-2028) & (USD Million) Table 73. Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Country (2017-2022) & (USD Million) Table 74. Middle East & Africa Skin and Soft Tissue Infection Treatment Revenue by Country (2023-2028) & (USD Million) List of Figures Figure 1. Skin and Soft Tissue Infection Treatment Picture Figure 2. Global Skin and Soft Tissue Infection Treatment Revenue Market Share by Type in 2021 Figure 3. Antibiotics Figure 4. Anti-Fungal Agents Figure 5. Others Figure 6. Skin and Soft Tissue Infection Treatment Revenue Market Share by Application in 2021 Figure 7. Hospitals Picture Figure 8. Clinics Picture Figure 9. Ambulatory Surgical Centers Picture Figure 10. Others Picture Figure 11. Global Skin and Soft Tissue Infection Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028 Figure 12. Global Skin and Soft Tissue Infection Treatment Revenue and Forecast (2017-2028) & (USD Million) Figure 13. Global Skin and Soft Tissue Infection Treatment Revenue Market Share by Region (2017-2028) Figure 14. Global Skin and Soft Tissue Infection Treatment Revenue Market Share by Region in 2021 Figure 15. North America Skin and Soft Tissue Infection Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 16. Europe Skin and Soft Tissue Infection Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 17. Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 18. South America Skin and Soft Tissue Infection Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 19. Middle East and Africa Skin and Soft Tissue Infection Treatment Revenue (USD Million) and Growth Rate (2017-2028) Figure 20. Skin and Soft Tissue Infection Treatment Market Drivers Figure 21. Skin and Soft Tissue Infection Treatment Market Restraints Figure 22. Skin and Soft Tissue Infection Treatment Market Trends Figure 23. Merck Recent Developments and Future Plans Figure 24. Wockhardt Limited Recent Developments and Future Plans Figure 25. Atox Bio Inc. Recent Developments and Future Plans Figure 26. Durata Therapeutics (Teva) Recent Developments and Future Plans Figure 27. Basilea Pharmaceutica AG Recent Developments and Future Plans Figure 28. Melinta Therapeutics Recent Developments and Future Plans Figure 29. Takeda Pharmaceutical Recent Developments and Future Plans Figure 30. Global Skin and Soft Tissue Infection Treatment Revenue Share by Players in 2021 Figure 31. Skin and Soft Tissue Infection Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021 Figure 32. Global Top 3 Players Skin and Soft Tissue Infection Treatment Revenue Market Share in 2021 Figure 33. Global Top 10 Players Skin and Soft Tissue Infection Treatment Revenue Market Share in 2021 Figure 34. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022) Figure 35. Global Skin and Soft Tissue Infection Treatment Revenue Share by Type in 2021 Figure 36. Global Skin and Soft Tissue Infection Treatment Market Share Forecast by Type (2023-2028) Figure 37. Global Skin and Soft Tissue Infection Treatment Revenue Share by Application in 2021 Figure 38. Global Skin and Soft Tissue Infection Treatment Market Share Forecast by Application (2023-2028) Figure 39. North America Skin and Soft Tissue Infection Treatment Sales Market Share by Type (2017-2028) Figure 40. North America Skin and Soft Tissue Infection Treatment Sales Market Share by Application (2017-2028) Figure 41. North America Skin and Soft Tissue Infection Treatment Revenue Market Share by Country (2017-2028) Figure 42. United States Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 43. Canada Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 44. Mexico Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 45. Europe Skin and Soft Tissue Infection Treatment Sales Market Share by Type (2017-2028) Figure 46. Europe Skin and Soft Tissue Infection Treatment Sales Market Share by Application (2017-2028) Figure 47. Europe Skin and Soft Tissue Infection Treatment Revenue Market Share by Country (2017-2028) Figure 48. Germany Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 49. France Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 50. United Kingdom Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 51. Russia Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 52. Italy Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 53. Asia-Pacific Skin and Soft Tissue Infection Treatment Sales Market Share by Type (2017-2028) Figure 54. Asia-Pacific Skin and Soft Tissue Infection Treatment Sales Market Share by Application (2017-2028) Figure 55. Asia-Pacific Skin and Soft Tissue Infection Treatment Revenue Market Share by Region (2017-2028) Figure 56. China Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 57. Japan Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 58. South Korea Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 59. India Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 60. Southeast Asia Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 61. Australia Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 62. South America Skin and Soft Tissue Infection Treatment Sales Market Share by Type (2017-2028) Figure 63. South America Skin and Soft Tissue Infection Treatment Sales Market Share by Application (2017-2028) Figure 64. South America Skin and Soft Tissue Infection Treatment Revenue Market Share by Country (2017-2028) Figure 65. Brazil Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 66. Argentina Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 67. Middle East and Africa Skin and Soft Tissue Infection Treatment Sales Market Share by Type (2017-2028) Figure 68. Middle East and Africa Skin and Soft Tissue Infection Treatment Sales Market Share by Application (2017-2028) Figure 69. Middle East and Africa Skin and Soft Tissue Infection Treatment Revenue Market Share by Country (2017-2028) Figure 70. Turkey Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 71. Saudi Arabia Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 72. UAE Skin and Soft Tissue Infection Treatment Revenue and Growth Rate (2017-2028) & (USD Million) Figure 73. Methodology Figure 74. Research Process and Data Source

Merck Wockhardt Limited Atox Bio Inc. Durata Therapeutics (Teva) Basilea Pharmaceutica AG Melinta Therapeutics Takeda Pharmaceutical